Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Acimtamig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Acimtamig: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Trastuzumab vedotin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Trastuzumab vedotin: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
VK-5211 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
VK-5211: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
LHP-588 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
LHP-588: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CV-9202 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
CV-9202: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
VK-2019 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
VK-2019: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ROSE-010 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
ROSE-010: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Polypegylated recombinant human interleukin-2(Mabwell Bioscience) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Polypegylated recombinant human interleukin-2(Mabwell Bioscience): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
VTX-2735 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
VTX-2735: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CERC-301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
CERC-301: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ORKA-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
ORKA-001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BGB-DXP604 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
BGB-DXP604: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.